300676 华大基因
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入1,871,451-9.67%4,349,6377,053,1516,766,1378,397,230
减:营业总成本1,787,315-10.92%4,110,9295,895,1405,076,2035,848,784
    其中:营业成本987,547-11.84%2,179,0313,366,2262,835,4233,353,046
               财务费用(26,961)39.05%(45,882)(8,421)104,262212,789
               资产减值损失(2,501)-87.10%(26,662)(318,456)(72,394)(109,392)
公允价值变动收益(7,106)-80.21%(34,357)80,73386,41252,204
投资收益(11,089)-137.27%1,285307,482173,818101,119
    其中:对联营企业和合营企业的投资收益(21,437)-445.16%(31,542)297,911111,684100,384
营业利润28,426-58.51%150,6491,087,9101,822,8352,498,174
利润总额25,334-59.58%115,5361,006,7921,745,8932,442,294
减:所得税费用5,181-59.22%21,854197,507268,195340,242
净利润20,153-59.66%93,682809,2861,477,6992,102,052
减:非控股权益1,9531,013.46%7816,52016,16211,767
股东净利润18,200-63.45%92,900802,7651,461,5362,090,285

市场价值指针
每股收益 (元) *0.043-64.36%0.2271.9563.5645.252
每股派息 (元) *----0.1001.0000.3500.350
每股净资产 (元) *24.1430.74%23.82024.34922.51314.772
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容